AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$RLMD

TRAVERSA SERGIO purchased $828K of RLMD

TRAVERSA SERGIO (Chief Executive Officer) purchased 200,000 shares of RELMADA THERAPEUTICS, INC. (RLMD) at an average of $4.14 ($4.10–$4.18, $0.83M total) across 2 trades over 2026-09-09 to 2026-09-10.

Original reporting
SEC EDGAR · TRAVERSA SERGIO
Published Sep 11, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 12:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RLMD
Bullish
medium confidence
Mentioned
$RLMD
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RLMDBullishLow
01

Why it matters

The purchase modestly raises confidence in management's outlook but is unlikely to move the stock significantly.

02

Market read

Primary insider purchase with limited material impact; relevant for traders tracking insider activity.

03

What to watch

Potential upcoming clinical data or financing events not disclosed in this filing.

Relevance 6/10Novelty 4/10Timing: post‑market filing

Background

Form 4 filings disclose insider transactions; RLMD is a biotech firm with ongoing clinical programs.

Company-level read

Ticker impact

$RLMDBullishMedium confidence
Context

CEO Sergio Traversa bought 200,000 shares for $828K, increasing his stake to 1.5M shares.

Expected impact

Potential short-term upside as market absorbs insider buying.

Evidence & confidence

A $828K open‑market purchase by the CEO is a primary disclosure but modest in size; it may attract attention from traders monitoring insider activity.

Market effects

Sector

Limited impact on biotech sector; insider buying is company‑specific.

Regional

No broader regional effect.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

Insider buying could be a routine portfolio rebalancing, not a strong bullish signal.

Key entities

  • Person
    Sergio Traversa

    Chief Executive Officer of Relmada Therapeutics, Inc.

  • Company
    Relmada Therapeutics, Inc.

    Biopharmaceutical company developing treatments for neuropsychiatric disorders.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RLMD insider trading history →

Related articles

AUG 14
$RLMDMed

Relmada (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics (RLMD) reported Q2 2026 results and an execution update. Cash was $217.7M at June 30, 2026, funding operations through 2029. Net loss was $12.9M ($0.11/share). Management expects IND filings for NDV-01 and sepranolone by end-2026 and Phase 3 RESCUE enrollment to start after IND clearance.

fool.com6 min
AUG 6
$RLMDMed

RELMADA THERAPEUTICS, INC. (RLMD): Results of Operations and Financial Condition

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ● Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational

SEC EDGAR 8-K6 min
SEP 11
$DELLLow

Silver Lake Partners V DE (AIV), L.P. (Durban Egon) sold $14.9M of DELL (indirect holdings)

Silver Lake Partners V DE (AIV), L.P. sold 27,629 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $540.39 ($534.09–$550.71, $14.93M total) across 17 trades on 2026-09-09. Filed jointly with Silver Lake Technology Associates V, L.P. (Director), SLTA V (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).

SEC EDGAR1 min
SEP 11
$DELLMed

Silver Lake Partners IV, L.P. (Durban Egon) sold $28.5M of DELL (indirect holdings)

Silver Lake Partners IV, L.P. sold 52,708 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $540.39 ($534.09–$550.71, $28.48M total) across 17 trades on 2026-09-09. Filed jointly with Silver Lake Technology Associates IV, L.P. (Director), SLTA IV (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).

SEC EDGAR1 min